Recommendations on the use of quadrivalent human papillomavirus vaccine in males - advisory committee on immunization practices (ACIP), 2011

Morbidity and Mortality Weekly Report

Volumn 60, Issue 50, 2011, Pages 1705-1708

  Dunne, Eileen F ^a   Markowitz, Lauri E ^a   Chesson, Harrell ^a   Robinette Curtis, C ^b   Saraiya, Mona ^c   Gee, Julianne ^d   Unger, Elizabeth R ^d  

^a Division of HIV/AIDS Prevention   (United States)

^b National Center for Immunizations and Respiratory Diseases   (United States)

^c NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ADVISORY COMMITTEE; ALPHAPAPILLOMAVIRUS; ANUS TUMOR; ARTICLE; CHILD; CONDYLOMA ACUMINATUM; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; OROPHARYNX TUMOR; PAPILLOMAVIRUS INFECTION; PENIS TUMOR; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; UNITED STATES; VIROLOGY;

ADOLESCENT; ADULT; ADVISORY COMMITTEES; ALPHAPAPILLOMAVIRUS; ANUS NEOPLASMS; CHILD; CONDYLOMATA ACUMINATA; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PENILE NEOPLASMS; UNITED STATES; YOUNG ADULT;

EID: 84255198571     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. CDC. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59:630-2.
2. Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ, ACIP Evidence Based Recommendations Work Group (EBRWG). Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). Vaccine 2011;29:9171-6.
3. CDC. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59:626-9.
4. Food and Drug Administration. Highlights of prescribing information. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18]). Silver Spring, MD: Food and Drug Administration; 2011. Available at http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm111263.pdf. Accessed December 13, 2011.
5. CDC. National and state vaccination coverage among adolescents aged 13 through 17 years-United States, 2010. MMWR 2011;60:1117-23.
6. Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the U.S. Cancer 2008;113(10 Suppl):2892-900.
7. Gillison ML, Chaturvedi AK, Lowy DR. HPV Prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008;113(10 Suppl):3036-46.
8. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-301.
9. Saraiya M. Burden of HPV-associated cancers in the United States. Presentation before the Advisory Committee on Immunization Practices (ACIP), February 24, 2011.
10. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Available at snameurlhttp://www.cdc.gov/vaccines/recs/acip/downloads/mtg- slides-feb11/11-2-hpv-rela-cancer.pdf. Accessed November 21 2011.
11. Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008;198:500-7.
12. Hoy T, Singhal PK, Willey VJ, Insinga RP. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009;25:2343-51.
13. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009;2:868-78.
14. Ferris D. A long-term extension study of Gardasil in adolescents. O-18.05. Proceedings of the 27th International Papillomavirus Conference and Clinical Workshop, September 17-22, 2011, Berlin, Germany.
15. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-7.
16. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink. Vaccine 2011;29;8279-84.
17. Velicer C. Post-licensure safety study of quadrivalent human papillomavirus vaccine among 189,629 females. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Presentation before the Advisory Committee on Immunization Practices (ACIP), October 25, 2011. Available at http://www.cdc.gov/VACCINes/recs/acip/downloads/mtg-slides-oct11/03-HPV-CVelicer.pdf. Accessed November 21, 2011.
18. Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009;12:343-51.
19. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009;339:b3884.
20. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010;28:6858-67.
21. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011;29:8443-50.
22. Chesson HW. HPV vaccine cost-effectiveness: updates and review. Presentation before the Advisory Committee on Immunization Practices (ACIP), June 22, 2011. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Available at http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-jun11/07-5-hpv-cost-effect.pdf. Accessed December 15, 2011.
23. Jin F, Prestage GP, Kippax SC, et al. Risk factors for genital and anal warts in a prospective cohort of HIV-negative homosexual men: the HIM study. Sex Transm Dis 2007;34:488-93.
24. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002;35:1127-34.
25. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010;10:845-52.
26. CDC. Sexually transmitted diseases treatment guidelines, 2010. MMWR 2010;59(No. RR-12).
27. Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med 2010;170:1337-45.
28. Levin MJ, Moscicki AB, Song LY, et al; IMPAACT P1047 Protocol Team. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010;55:197-204.
29. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010;202:1246-53.